Niemann-Pick Disease, Type C1
Conditions
Brief summary
The purpose of this study is to provide continued access to treatment for NPC-1 after participation and completion of the Phase I trial CTD-TCNPC-101, when administered at doses of 1500 mg/kg and 2500 mg/kg by slow IV infusion over a period of 8 to 9 hours every two weeks.
Detailed description
This is an open-label extension study of intravenous HP-β-CD (administered as Trappsol® Cyclo(TM)) in patients with NPC-1 to evaluate long-term safety and efficacy by providing continued access to treatment following completion of study CTD-TCNPC-101. Patients will receive medication at their home or local site under the supervision of a home nurse professional or at the parent site under the supervision of the site principal investigator. Patients will visit the parent site for safety and efficacy evaluations after receiving treatment for 3 months in the extension protocol. Thereafter, visits to the parent site will be every 6 months until cessation. The study will continue until Trappsol® Cyclo (TM) becomes commercially available or study/site/patient discontinuation. All patients who complete study CTD-TCNCP-101 and pass the screening criteria will be eligible for this study. The study will be directed from parent site in the US. Vital signs, AEs Adverse Events (AEs) and concomitant meds will be recorded by the home nurse professional or deputy at the local site and reported immediately to the parent site for entry into the Electronic Data Capture (EDC) and reporting to the sponsor. For logistical reasons home infusions will be permitted as long as AEs, infusion details and concomitants medications are reported directly to the parent site by an authorised deputy according to local guidelines. A Safety Review Committee (SRC) consisting of an independent advisor, the medical monitor, and the principal investigator will be established to review AEs and laboratory data throughout the study.
Interventions
DRUGHydroxypropyl-β-cyclodextrin
HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
Sponsors
Cyclo Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Completion of study CTD-TCNPC-101 with no safety concerns at the final visit * Negative urine pregnancy test for females of child bearing potential * Patients must be legally resident in the USA with access to healthcare * Written, informed consent
Exclusion criteria
* Inability to comply with the proposed protocol assessments or any uncertainty about their ability to give meaningful, informed consent (legal guardian may give consent with subject assent) * Concurrent medical conditions representing a contraindication to any of the study medications * Grade 3 renal impairment or worse as indicated by estimated Glomerular filtration rate (eGFR) \< 60mL/min/1.73m2 * Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or International Normalised Ratio (INR) \>1.8 * Male patients and female patients of childbearing potential who are not willing to use appropriate birth control (i.e. double barrier birth control) from enrollment until the follow-up visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events (AEs): Frequency, severity, time to onset, duration, and relatedness to study product | 1-104 weeks | Adverse events (AEs): Frequency, severity, time to onset, duration, and relatedness to study product |
| Serious adverse events (SAEs): Frequency, severity, time to onset, duration and relatedness to study product | 1-104 weeks | Serious adverse events (SAEs): Frequency, severity, time to onset, duration and relatedness to study product |
| Number of discontinuations due to AEs: Patient Discontinuation, Study Treatment Discontinuation, Study and Site Discontinuation | 1-104 weeks | Discontinuation, Study and Site Discontinuation |
| Auditory capacity will be measured by behavioral auditory assessment | 1-104 weeks | Auditory capacity will be measured by behavioral auditory assessment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in total score as well as individual National Institute of Health (NIH) Niemann-Pick Disease Type C (NPC) Severity Scale (NCSS) | 1-104 weeks | Change from baseline in total score as well as individual National Institute of Health (NIH) Niemann-Pick Disease Type C (NPC) Severity Scale (NCSS) |
Countries
United States
Outcome results
None listed